FAP-alpha chimeric antigen receptor T-cell

FAP-alpha chimeric antigen receptor T-cell therapy is an engineered cellular immunotherapy designed to target Fibroblast Activation Protein alpha (FAPα), a cell surface protein predominantly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment and on certain solid tumor cells. By specifically targeting the CAF-rich stroma, these CAR-T cells aim to dismantle the physical and biochemical barriers that contribute to immunosuppression and treatment resistance in solid malignancies. Optieum Biotechnologies has developed optimized FAPα CAR-T clones, such as FL12, using a high-throughput scFv library system (Eumbody System) to fine-tune binding affinity. This optimization is intended to mitigate trogocytosis and T-cell exhaustion, thereby enhancing the persistence and anti-tumor efficacy of the cells, as demonstrated in preclinical models of glioblastoma.

Other names

FAP-alpha CAR-TFAP CAR-Tanti-FAP CAR-T